Drs. Rachael Murray and Emma O’Dowd say despite increasing evidence that cessation efforts within screening programs are effective, a lack of clear guidance means this opportunity is often missed. Read more
Dana-Farber's Dr. Alice Shaw recently explored various combination strategies that show promise in preventing or delaying resistance in this previously undruggable space. Read more
During his award lecture at the European Lung Cancer Congress, Dr. Kerr said lung cancer treatment has benefited from the bridging of the historical divide between pathology and medical oncology. Read more
During a TTLC debate, Drs. Helena Yu and Shirish Gadgeel weighed the pros and limitations of osimertinib monotherapy and combination therapies. Read more
Lacking evidence to argue against combinations in this patient population, Dr. Penelope Bradbury, turned to humor to make her case. Read more
Drs. Jonathan W. Riess and Greg Kalemkerian present opposing views regarding the therapeutic potential of novel targeted therapies. Read more
While Dr. Trever Bivona argued that KRAS inhibitors will join other seminal oncogene inhibitors, Dr. Rebecca Heist said the data has yet to demonstrate they outperform the current second-line standard of care. Read more
Narjust Florez, MD, and Angela Morabito, BS, launched the #HearHer campaign to raise awareness about the increasing incidence of lung cancer among women and the frequent delays in diagnosis. Read more
Poet and ILCN Editor-in-Chief Corey Langer, MD, illustrates the build-up and anticipation surrounding the release of research data. Read more
Heidi Nafman-Onda, founder of The White Ribbon Project, shares her experience discovering and grappling with the long-term effects of radiation therapy and addresses the need for coordinated survivorship care. Read more